Measurement of urinary kidney injury molecule-1 as a predictive biomarker of contrast-induced acute kidney injury
DOI:
https://doi.org/10.22317/jcms.v3i9.133Abstract
Objective The aim of the present study is to evaluate the urinary KIM-1 level in the patients after 24 h angiography as a predictive biomarker of contrast-induced acute kidney injury.
Methods This study included 80 selective patients attending in the cardiology unit (48 males, 32 females). The study was conducted in the cardiac catheterization unit at Al- Hussein Medical City/ Kerbala. Clinical examination and laboratory investigations were made before and 24 h after angiography, these investigations include: serum creatinine, blood urea and estimated GFR. Urinary KIM-1 was measured before and after 24 h angiography.
Results There was no significant difference in urinary KIM-1 when compared between CIN and non CIN group P > 0.05. The level of urinary KIM-1 increased in the patients after 24 h of angiography when compared with baseline level of P < 0.001.
Conclusion Urinary KIM-1 was not useful for predicting or detecting CIN. But urinary KIM-1 level may be useful as a biomarker for tubular damage following intravascular administration of contrast media, 24 h.
References
Tanaga K, Tarao K, Nakamura Y, Inoue T, Jo K, Ishikawa T, et al. Percutaneous coronary intervention causes increase of serum cystatin C concentration even in the patients with a low risk of contrast-induced nephropathy. Cardiovasc Interv Ther. 2012;27:168–173.
Brown JR, Rezaee ME, Nichols EL, Marshall EJ, Siew ED, Matheny ME. Incidence and in‐hospital mortality of Acute Kidney Injury (AKI) and dialysis‐requiring AKI (AKI‐D) after cardiac catheterization in the national inpatient sample. J Am Heart Assoc. 2016;5:e002739.
Cely CM, Schein RM, Quartin AA. Risk of contrast induced nephropathy in the critically ill: a prospective, case matched study. Critical Care. 2012;16:1.
Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, Malyszko JS, Dobrzycki S. Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Renal Failure. 2009;31:910–919. 5. Parfrey P. The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Interv Radiol. 2005;28:S3–11.
Palevsky PM. Defining contrast-induced nephropathy. Clin J Am Soc Nephrol. 2009;4:1151–1153.
Morcos SK. Prevention of contrast media–induced nephrotoxicity after angiographic procedures. J Vasc Interv Radiol. 2005;6:13–23.
Hojs R, Ekart R, Bevc S, Hojs N. Biomarkers of Renal disease and progression in patients with diabetes. J Clin Med. 2015;4:1010–1024.
Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediat. 2011;23:194.
Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Ann Rev Pharmacol Toxicol. 2008;48:463.
Carlsson AC, Larsson A, Helmersson-Karlqvist J, Lind L, Ingelsson E, Larsson TE, et al. Urinary kidney injury molecule-1 and the risk of cardiovascular mortality in elderly men. Clin J Am Soc Nephrol. 2014;CJN–11901113.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
Assareh A, Yazdankhah S, Majidi S, Nasehi N, Mousavi SS. Contrast induced nephropathy among patients with normal renal function undergoing coronary angiography. J Renal Inj Prev. 2016;5:21.
Sato A, Aonuma K, Watanabe M, Hirayama A, Tamaki N, Tsutsui H, et al. Association of contrast-induced nephropathy with risk of adverse clinical outcomes in patients with cardiac catheterization: From the CINC-J study. International Journal of Cardiology. 2017 Jan. 15;227:424–9.
Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al. Contrast-induced nephropathy: updated ESUR contrast media safety committee guidelines. Eur Radiol. 2011;21:2527–2541.
Helmersson-Karlqvist J, Ärnlöv J, Carlsson AC, Lind L, Larsson A. Urinary KIM-1, but not urinary cystatin C, should be corrected for urinary creatinine. Clin Biochem. 2016;49:1164–1166.
Akdeniz D, Celik HT, Kazanci F, Yilmaz H, Yalcin S, Bilgic MA, et al. Is kidney injury molecule 1 a valuable tool for the early diagnosis of contrast-induced nephropathy? J Invest Med. 2015;63:930–934.
Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, Malyszko JS, Dobrzycki S. Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Renal Failure. 2009;31:910–919.
Kooiman J, Pasha SM, Zondag W, Sijpkens YW, van der Molen AJ, Huisman MV, et al. Meta-analysis: serum creatinine changes following contrast enhanced CT imaging. Eur J Radiol. 2012;81:2554–2561.
Perico N, Cattaneo D, Remuzzi G. Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. Am J Kidney Dis. 2009;53:1–4.
Kwok CS, Pang CL, Yeong JK, Loke YK. Measures used to treat contrast-induced nephropathy: overview of reviews. Br J Radiol. 2013;86:20120272.
Huang Y, Craig Don-Wauchope A. The clinical utility of kidney injury molecule 1 in the prediction, diagnosis and prognosis of acute kidney injury: a systematic review. Inflam Allergy Drug Targets. 2011;10:260–271
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
